Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats

Pharmacological Research

Volumn 90, Issue , 2014, Pages 36-47

  Balakumar, Pitchai ^a   Varatharajan, Rajavel ^a   Nyo, Ying Hui ^a   Renushia, Raja ^a   Raaginey, Devarajan ^a   Oh, Ann Nah ^a   Akhtar, Shaikh Sohrab ^a   Rupeshkumar, Mani ^a   Sundram, Karupiah ^a   Dhanaraj, Sokkalingam A ^a  

^a AIMST UNIVERSITY   (Malaysia)

Author keywords

Diabetes mellitus; Lipid alteration; Low dose dipyridamole; Low dose fenofibrate; Nephropathy; Uric acid elevation

Indexed keywords

DIPYRIDAMOLE; EOSIN; FENOFIBRATE; HEMATOXYLIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LISINOPRIL; STREPTOZOCIN; TRIACYLGLYCEROL; URIC ACID; CHOLESTEROL; CREATININE; GLUCOSE BLOOD LEVEL; PROTECTIVE AGENT; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; HYPERURICEMIA; KIDNEY MASS; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; PERIODIC ACID SCHIFF STAIN; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; ANIMAL; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG COMBINATION; DRUG EFFECTS; KIDNEY; ORGAN SIZE; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD GLUCOSE; CHOLESTEROL; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; FENOFIBRATE; KIDNEY; LIPOPROTEINS, HDL; LISINOPRIL; MALE; ORGAN SIZE; PROTECTIVE AGENTS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES; UREA; URIC ACID;

EID: 84908153783     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.08.008     Document Type: Article

References (54)

1. P. Balakumar, M.K. Arora, S.S. Ganti, J. Reddy, and M. Singh Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions Pharmacol Res 60 2009 24 32
2. N. Malandrino, W.C. Wu, T.H. Taveira, H.B. Whitlatch, and R.J. Smith Association between red blood cell distribution width and macrovascular and microvascular complications in diabetes Diabetologia 55 2012 226 235
3. Y.S. Kanwar, J. Wada, L. Sun, P. Xie, E.I. Wallner, and S. Chen Diabetic nephropathy: mechanisms of renal disease progression Exp Biol Med 233 2008 4 11
4. P. Balakumar, M.K. Arora, J. Reddy, and M.B. Anand-Srivastava Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism J Cardiovasc Pharmacol 54 2009 129 138
5. P. Balakumar, V.A. Chakkarwar, and M. Singh Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat Mol Cell Biochem 320 2009 149 162
6. D.I. Jalal, D.M. Maahs, P. Hovind, and T. Nakagawa Uric acid as a mediator of diabetic nephropathy Semin Nephrol 31 2011 459 465
7. I. Kouroumichakis, N. Papanas, P. Zarogoulidis, V. Liakopoulos, E. Maltezos, and D.P. Mikhailidis Fibrates: therapeutic potential for diabetic nephropathy Eur J Intern Med 23 2012 309 316
8. L.G. Hunsicker Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control J Manag Care Pharm 10 2004 S12 S17
9. P. Balakumar, M.K. Arora, and M. Singh Emerging role of PPAR ligands in the management of diabetic nephropathy Pharmacol Res 60 2009 170 173
10. P. Balakumar, H.K. Bishnoi, and N. Mahadevan Telmisartan in the management of diabetic nephropathy: a contemporary view Curr Diabetes Rev 8 2012 183 190
11. L.A. Leiter The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering Diabetes Res Clin Pract 68 2005 S3 S14
12. P. Balakumar, S. Kadian, and N. Mahadevan Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney? Pharmacol Res 65 2012 430 436
13. M. Herman-Edelstein, P. Scherzer, A. Tobar, M. Levi, and U. Gafter Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy J Lipid Res 55 2014 561 572
14. J.C. Ansquer, C. Foucher, P. Aubonnet, and K. Le Malicot Fibrates and microvascular complications in diabetes - insight from the FIELD study Curr Pharm Des 15 2009 537 552
15. A.C. Frazier-Wood, J.M. Ordovas, R.J. Straka, J.E. Hixson, I.B. Borecki, and H.K. Tiwari The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study Pharmacogenomics J 13 2013 312 317
16. C.W. Park, Y. Zhang, X. Zhang, J. Wu, L. Chen, and D.R. Cha PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice Kidney Int 69 2006 1511 1517
17. J.C. Ansquer, C. Foucher, S. Rattier, M.R. Taskinen, G. Steiner DAIS Investigators Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) Am J Kidney Dis 45 2005 485 493
18. L. Li, N. Emmett, D. Mann, and X. Zhao Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy Exp Biol Med (Maywood) 235 2010 383 391
19. S. Chung, and C.W. Park Role of peroxisome proliferator-activated receptor α in diabetic nephropathy Diabetes Metab J 35 2011 327 336
20. 1 receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat Pharmacol Res 66 2012 349 356
21. M.K. Arora, K. Reddy, and P. Balakumar The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy Eur J Pharmacol 636 2010 137 144
22. S. Kadian, N. Mahadevan, and P. Balakumar Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy Eur J Pharmacol 698 2013 388 396
23. M.C. Acelajado, and S. Oparil Antiplatelet therapy for transient ischemic attack J Clin Hypertens (Greenwich) 14 2012 103 111
24. F. Vargas, C. Rivas, Y. Díaz, N. Contreras, A. Silva, and L.E. Ojeda Antioxidant properties of dipyridamole as assessed by chemiluminescence Pharmazie 58 2003 817 823
25. S.B. Zhuplatov, T. Masaki, D.K. Blumenthal, and A.K. Cheung Mechanism of dipyridamole's action in inhibition of venous and arterial smooth muscle cell proliferation Basic Clin Pharmacol Toxicol 99 2006 431 439
26. M.M. Soliman, and M.M. Arafah Treatment with dipyridamole improves cardiac function and prevent injury in a rat model of hemorrhage Eur J Pharmacol 678 2012 26 31
27. P. Balakumar, Y.H. Nyo, R. Renushia, D. Raaginey, A.N. Oh, and R. Varatharajan Classical and pleiotropic actions of dipyridamole: not enough light to illuminate the dark tunnel? Pharmacol Res 87C 2014 144 150
28. A.H. Hopper, H. Tindall, and J.A. Davies Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy Nephrol Dial Transplant 4 1989 140 143
29. P. Khajehdehi, J. Roozbeh, and H. Mostafavi A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy Scand J Urol Nephrol 36 2002 145 148
30. T. Aizawa, S. Suzuki, T. Asawa, M. Komatsu, S. Shigematsu, and N. Okada Dipyridamole reduces urinary albumin excretion in diabetic patients with normo- or microalbuminuria Clin Nephrol 33 1990 130 135
31. L.C. Becker Conditions for vasodilator-induced coronary steal in experimental myocardial ischemia Circulation 57 1978 1103 1110
32. J. Ando, H. Yasuda, T. Kobayashi, A. Miyamoto, K. Kanamori, and R. Murakami Conditions for coronary steal caused by coronary vasodilator in man Jpn Heart J 23 1982 79 95
33. Y. Ye, Y. Lin, R. Perez-Polo, M.H. Huang, M.G. Hughes, and D.J. McAdoo Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination Am J Physiol Heart Circ Physiol 293 2007 813 818
34. A.K. Sharma, D. Khanna, and P. Balakumar Low-dose dipyridamole treatment partially prevents diabetes mellitus-induced vascular endothelial and renal abnormalities in rats Int J Cardiol 172 2014 530 532
35. T. Szkudelski The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas Physiol Res 50 2001 537 546
36. J. Singh, S. Budhiraja, H. Lal, and B.R. Arora Renoprotection by telmisartan versus benazepril in streptozotocin induced diabetic nephropathy Iranian J Pharmacol Ther 5 2006 135 139
37. J.L. Lyman Blood urea nitrogen and creatinine Emerg Med Clin North Am 4 1986 223 233
38. V. Tsimihodimos, A. Kakafika, and M. Elisaf Fibrate treatment can increase serum creatinine levels Nephrol Dial Transplant 16 2001 1301
39. C.R. McQuade, J. Griego, J. Anderson, and A.B. Pai Elevated serum creatinine levels associated with fenofibrate therapy Am J Health Syst Pharm 65 2008 138 141
40. C. Hottelart, N. el Esper, J.M. Achard, A. Pruna, and A. Fournier Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency Nephrologie 20 1999 41 44
41. C. Hottelart, N. el Esper, F. Rose, J.M. Achard, and A. Fournier Fenofibrate increases creatininemia by increasing metabolic production of creatinine Nephron 92 2002 536 541
42. P. Hovind, P. Rossing, R.J. Johnson, and H.H. Parving Serum uric acid as a new player in the development of diabetic nephropathy J Ren Nutr 21 2011 124 127
43. P. Hovind, P. Rossing, L. Tarnow, R.J. Johnson, and H.H. Parving Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study Diabetes 58 2009 1668 1671
44. S. Behradmanesh, M.K. Horestani, A. Baradaran, and H. Nasri Association of serum uric acid with proteinuria in type 2 diabetic patients J Res Med Sci 18 2013 44 46
45. J. Ran, J. Ma, Y. Liu, R. Tan, H. Liu, and G. Lao Low protein diet inhibits uric acid synthesis and attenuates renal damage in streptozotocin-induced diabetic rats J Diabetes Res 2014 2014 287536
46. M.M. Anwar, and A.R. Meki Oxidative stress in streptozotocin-induced diabetic rats: effects of garlic oil and melatonin Comp Biochem Physiol A Mol Integr Physiol 135 2003 539 547
47. G. Saravanan, P. Ponmurugan, G.P. Senthil Kumar, and T. Rajarajan Antidiabetic properties of S-allyl cysteine, a garlic component on streptozotocin-induced diabetes in rats J Appl Biomed 7 2009 151 159
48. Y.H. Lee, C.H. Lee, and J. Lee Effect of fenofibrate in combination with urate lowering agents in patients with gout Korean J Intern Med 21 2006 89 93
49. D. Uetake, I. Ohno, K. Ichida, Y. Yamaguchi, H. Saikawa, and H. Endou Effect of fenofibrate on uric acid metabolism and urate transporter 1 Intern Med 49 2010 89 94
50. D. Taneja, J. Thompson, P. Wilson, K. Brandewie, L. Schaefer, and B. Mitchell Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice J Lipid Res 51 2010 1464 1470
51. T. Kuwabara, K. Mori, M. Mukoyama, M. Kasahara, H. Yokoi, and Y. Saito Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice Diabetologia 55 2012 2256 2266
52. V. Vallon, and H. Osswald Dipyridamole prevents diabetes-induced alterations of kidney function in rats Naunyn Schmiedebergs Arch Pharmacol 349 1994 217 222
53. N.K. Agrawal, and U. Gupta The effect of Lisinopril on blood glucose level given alone and in combination with oral antidiabetic drugs in alloxan-induced diabetic rats Afr J Pharmacol Ther 2 2013 59 65
54. A.D. Morris, D.I. Boyle, A.D. McMahon, H. Pearce, J.M. Evans, and R.W. Newton ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit Diabetes Care 20 1997 1363 1367